CA2822684A1 - Oprf/i agents and their use in hospitalized and other patients - Google Patents

Oprf/i agents and their use in hospitalized and other patients Download PDF

Info

Publication number
CA2822684A1
CA2822684A1 CA2822684A CA2822684A CA2822684A1 CA 2822684 A1 CA2822684 A1 CA 2822684A1 CA 2822684 A CA2822684 A CA 2822684A CA 2822684 A CA2822684 A CA 2822684A CA 2822684 A1 CA2822684 A1 CA 2822684A1
Authority
CA
Canada
Prior art keywords
oprf
seq
agent
bond
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2822684A
Other languages
English (en)
French (fr)
Inventor
Christoph Klade
Robert Schlegl
Kerstin Westritschnig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of CA2822684A1 publication Critical patent/CA2822684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2822684A 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients Abandoned CA2822684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061426760P 2010-12-23 2010-12-23
US61/426,760 2010-12-23
PCT/EP2011/054127 WO2012084272A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Publications (1)

Publication Number Publication Date
CA2822684A1 true CA2822684A1 (en) 2012-06-28

Family

ID=44210049

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2822684A Abandoned CA2822684A1 (en) 2010-12-23 2011-03-18 Oprf/i agents and their use in hospitalized and other patients

Country Status (11)

Country Link
US (1) US20130266575A1 (enExample)
EP (1) EP2655402A1 (enExample)
JP (2) JP5893640B2 (enExample)
KR (1) KR20130133212A (enExample)
CN (1) CN103270047A (enExample)
AU (1) AU2011348396A1 (enExample)
BR (1) BR112013016254A2 (enExample)
CA (1) CA2822684A1 (enExample)
MX (1) MX2013007146A (enExample)
WO (1) WO2012084272A1 (enExample)
ZA (1) ZA201304235B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CN103983793A (zh) * 2014-05-29 2014-08-13 上海理工大学 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法
EP3185897A4 (en) * 2014-08-29 2018-05-02 Sorrento Therapeutics, Inc. Antibody therapeutics that bind oprf and opri
CN107922482A (zh) 2015-05-01 2018-04-17 英伊布里克斯有限合伙公司 Iii型分泌系统靶向分子
WO2016193402A1 (en) 2015-06-03 2016-12-08 Valneva Austria Gmbh Pseudomonas vaccine
CN114106178A (zh) 2015-07-16 2022-03-01 印希比股份有限公司 多价和多特异性结合dr5的融合蛋白
FR3099160B1 (fr) * 2019-07-23 2022-05-06 Univ Grenoble Alpes Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant
CN117222740A (zh) * 2022-06-07 2023-12-12 南方科技大学 编码PcrV和/或OprF-I蛋白的mRNA疫苗
CN116251178A (zh) * 2023-03-28 2023-06-13 吉林农业大学 一种铜绿假单胞菌疫苗及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5494672A (en) * 1989-04-28 1996-02-27 S.P.I. Synthetic Peptides Incorporated Pseudomonas peptide composition and method
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
EP0717106B1 (en) * 1994-12-16 2000-03-15 Chiron Behring Gmbh & Co. Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20040197341A1 (en) * 2001-09-03 2004-10-07 Jean-Claude Pechere Therapeutic process for p. aeruginosa infections using macrolide antibiotics
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP1623229A2 (en) 2003-05-15 2006-02-08 Cytos Biotechnology AG Selection of b cells with specificity of interest: method of preparation and use
GB0410958D0 (en) * 2004-05-15 2004-06-16 Haptogen Ltd Methods for reducing biofilm formation in infectious bacteria
CN101076342A (zh) * 2004-12-17 2007-11-21 维纳斯药业有限公司 用于对治疗感染提供总解决方案的抗生素组合
EP1921142A1 (en) 2006-11-07 2008-05-14 Cytos Biotechnology AG Selection of human monoclonal antibodies by eukaryotic cell display
US9987344B2 (en) * 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations

Also Published As

Publication number Publication date
ZA201304235B (en) 2014-09-25
AU2011348396A1 (en) 2013-07-04
EP2655402A1 (en) 2013-10-30
CN103270047A (zh) 2013-08-28
US20130266575A1 (en) 2013-10-10
JP2016147867A (ja) 2016-08-18
BR112013016254A2 (pt) 2017-07-11
JP5893640B2 (ja) 2016-03-23
KR20130133212A (ko) 2013-12-06
WO2012084272A1 (en) 2012-06-28
MX2013007146A (es) 2013-11-01
AU2011348396A2 (en) 2013-07-11
JP2014504297A (ja) 2014-02-20

Similar Documents

Publication Publication Date Title
US20130266575A1 (en) OprF/I AGENTS AND USE THEREOF IN HOSPITALIZED AND OTHER PATIENTS
CN111690059B (zh) 一种抗SARS-CoV-2的单克隆抗体1D7
AU2014259474B2 (en) Stabilized soluble prefusion RSV F polypeptides
JP6048845B2 (ja) ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
US20160176932A1 (en) Stabilized soluble pre-fusion rsv f polypeptides
CN112521494B (zh) 一种抗SARS-CoV-2的单克隆抗体2B11
CN111732654B (zh) 一种抗SARS-CoV-2的单克隆抗体1E10
EP3743106B1 (en) Influenza virus vaccines and uses thereof
EP3805255A1 (en) Acinetobacter baumannii immunogenic protein and composition and application thereof
KR102094569B1 (ko) 돼지의 부종병을 예방하는 백신
WO2023246853A1 (zh) 抗新型冠状病毒人源化多价结合蛋白及其应用
Burkhardt et al. Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A
US20150017684A1 (en) Streptococcus pyogenes antigens and corresponding dna fragments
US20160362480A1 (en) Novel oprf/i fusion proteins, their preparation and use
HK1188799A (en) Oprf/i agents and their use in hospitalized and other patients
CN113817051B (zh) 一种抗SARS-CoV-2的单克隆抗体1B6
US10774135B2 (en) Variant antibodies that bind AIP2
CN105542003A (zh) 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
TW202100540A (zh) 一種以重組毒素製作抗蛇毒血清方法
CN113817050A (zh) 一种抗SARS-CoV-2的单克隆抗体1H8
CN116270998A (zh) 基于双受体结合区rbd组装的多价生物毒素抗原疫苗及其制备方法与应用
CN110938150A (zh) E型肉毒毒素重组hn-l抗原的制备方法及其应用
HK40031633A (en) Influenza virus vaccines and uses thereof
NZ752808B2 (en) Stabilized soluble prefusion rsv f polypeptides
NZ713371B2 (en) Stabilized soluble prefusion rsv f polypeptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160309

FZDE Discontinued

Effective date: 20180320